The Glycobiology of Cancer (day 1) - In-Person Session
01:00 PM-05:00 PM(EST)
Virtual
NIH Videocast,
Bethesda, MD - 20892
Max.Capacity: 1000 No Participants
Agenda:
September 16, 2021
1:00-5:00p.m., EDT
Session I: Cancer Progression & Metastasis
Chair, Dr. Karl Krueger, Program Director, NCI
1:00p.m., Dr. Gerard C. Blobe, Duke University Medical School
Loss of ALK4 Function Promotes Cancer Progression Through Reprogramming of Receptor Glycosylation
1:30p.m., Dr. Kevin Yarema, Johns Hopkins Medical School
Metabolic Glycoengineering Labeling of Sialic Acid for Early Cancer Detection
2:00p.m., Dr. Prakash Radhakrishnan, University of Nebraska Medical Center
Cancer-associated Short O-glycans in Pancreatic Cancer Malignancy
2:30p.m., Dr. Charles Dimitroff, Florida International University
The Role of Hypoxia Driving Melanoma Glycobiology Signature
3:00p.m., Break
Session II: Diagnostics & Therapeutics
Chair, Dr. Neeraja Sathyamoorthy, Program Director, NCI
3:15p.m., Dr. Joseph Contessa, Yale University Medical School
Developing an Inhibitor of N-glycosylation for Cancer Therapy
3:45p.m., Dr. Steven Banik, Stanford University
Targeted Protein Degradation from the Extracellular Space
4:00p.m., Dr. Mia L. Huang, Scripps Department of Molecular Medicine
Tools to Discover and Surveil Glycoconjugate Targets in Cancer Biology
4:15p.m., Dr. Dannielle Engle, Salk Institute for Biological Studies
Interception of the Aberrant Glycan CA19-9 in Pancreatic Disease
4:30p.m., Dr. Edgar Engleman, Stanford University School of Medicine
Targeting Dectin-2 for Tumor Immunotherapy
5:00p.m., Adjourn